Alfuzosin: An α1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 5, 2006, Pages 583-596

  Elhilali, Mostafa M ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Adrenergic antagonists; Alfuzosin; Prostatic hyperplasia; Quality of life

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; CIMETIDINE; CYTOCHROME P450 3A4; DILTIAZEM; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; HYDROCHLOROTHIAZIDE; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PRAZOSIN; RITONAVIR; SILDENAFIL; SILYBUM MARIANUM EXTRACT; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL; WARFARIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; QUINAZOLINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BINDING AFFINITY; BLADDER CATHETERIZATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LIBIDO; LIVER FAILURE; MALE; MEDICAL DECISION MAKING; NONHUMAN; ORTHOSTATIC HYPOTENSION; PENIS ERECTION; PHYTOTHERAPY; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; RESIDUAL VOLUME; RESPIRATORY TRACT INFECTION; SEXUAL FUNCTION; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; SYNCOPE; URINARY TRACT DISEASE; URINE RETENTION; VASODILATATION; AGED; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL DYSFUNCTION; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, ALPHA-1; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; URODYNAMICS; UROLOGIC DISEASES;

EID: 33645835906     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.5.583     Document Type: Article

References (88)

1. POOL JL, KIRBY RS: Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int. Urol. Nephrol. (2001) 33(3):407-412.
2. KUMAR VL, DEWAN S: Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate. Int. Urol. Nephrol. (2000) 32(1):67-71.
3. AUA PRACTICE GUIDELINES COMMITTEE: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J. Urol. (2003) 170:530-547.
4. HIEBLE JP, RUFFOLO RR Jr: The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol. Res. (1996) 33(3):145-160.
5. BASAR MM, ATAN A, OZERGIN O, YILDIZ M: The efficacy of alfuzosin treatment in patients with prostatism. Int. Urol. Nephrol. (2001) 33(3):493-497.
6. ROEHRBORN CG, BARTSCH G, KIRBY R et al.: Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative international overview. Urology (2001) 58(5):642-650.
7. CHUTE CG, PANSER LA, GIRMAN CJ et al.: The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol. (1993) 150:85-89.
8. FURUYA S, KUMAMOTO Y, YOKOYAME E et al.: Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. (1982) 128:836.
9. ANDERSSON KE: Prostatic and extraprostatic alpha-adrenoceptors-contributions to the lower urinary tract symptoms in benign prostatic hyperplasia. Scand. J. Urol. Nephrol. (1996) 179:105.
10. CHAPPLE CR: Alpha adrenoceptor antagonists in the year 2000: is there anything new. Curr. Opin. Urol. (2001) 11:9-16.
11. DEBRUYNE FM: Alpha blockers: are all created equal? Urology (2000) 56(5 Suppl. 1):20-22.
12. HEIMBACH D, MULLER SC: [Treatment of benign prostatic hyperplasia with alpha 1-adrenoreceptor antagonists]. Urologe A. (1997) 36(1):18-34.
13. NICKEL JC, HERSCHORN S, CORCOS J et al.: Canadian guidelines for the management of benign prostatic hyperplasia. Can. J. Urol. (2005) 12(3):2677-2683.
14. DUTKIEWICS S: Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int. Urol. Nephrol. (2001) 32(3):423-432.
15. LOWE F: Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. (1999) 2(3):110-119.
16. ANDERSSON KE, LEPOR H, WYLLIE MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate (1997) 30(3):202-215.
17. LANGER SZ: History and nomenclature of alpha1-adrenoceptors. Eur. Urol. (1999) 36(Suppl. 1):2-6.
18. FAURE C, PIMOULE C, VALLANCIEN G, LANGER SZ, GRAHAM D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. (1994) 54(21):1595-1605.
19. NASU K, MORIYAMA N, KAWABE K et al.: Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br. J. Pharmacol. (1996) 119:797-803.
20. WYLLIE MG: Uroselectivity: end of the road? BJU Int. (2003) 92:141-142.
21. MARTIN DJ, LLUEL P, GUILLOT E, COSTE A, JAMMES D, ANGEL I: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J. Pharmacol. Exp. Ther. (1997) 282(1):228-235.
22. FLAVAHAN NA, VANHOUTTE PM: Alpha-adrenoceptor sub-classification in vascular smooth muscle. Trends Pharmacol. Sci. (1986) 7:347-349.
23. MURAMATSU I, OHMURA T, KIGOSHI S, HASHIMOTO S, OSHITA M: Pharmacological subclassification of alpha1-adrenoceptors in vascular smooth muscle. Br. J. Pharmacol. (1990) 99:197-201.
24. WALDEN PD, GERARDI C, LEPOR H: Localization and expression of the alpha 1A-1, alpha 1B and alpha 1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J. Urol. (1999) 161:635-640.
25. ROEHRBORN CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology (2001) 58(6 Suppl. 1):55-63.
26. ECKERT RE, SCHREIER U, ALLOUSSI S et al.: Zellulare Grndlage der dynamischen, infravesikalen Obstruktion im Rahmen der benignen Prostatahyperplasie: Rolle von Alpharezeptorenblockern und zyklischen. Nukleotiden. Akt Urol. (1998) 29:252-260.
27. ECKERT RE, SCHREIER U, ALLOUSSI S et al.: Prostate selectivity of alpha-1-adrenoceptors. J. Urol. (1995) 233(Suppl. 4):233.
28. MOTTET N, BRESSOLLE F, DELMAS V, ROBERT M, COSTA P: Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur. Urol. (2003) 44(1):101-105.
29. BUZELIN JM, DELAUCHE-CAVALLIER MC, ROTH S, GEFFRIAUD-RICOUARD C, SANTONI JP: Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br. J. Urol. (1997) 79(6):898-904.
30. BUZELIN JM, ROTH S, GEFFRIAUD-RICOUARD C, DELAUCHE-CAVALLIER MC: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur. Urol. (1997) 31(2):190-198.
31. LUKACS B, BLONDIN P, MACCARTHY C, DU BB, GRIPPON P, LASSALE C: Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur. Urol. (1996) 29(1):29-35.
32. LUKACS B, GRANGE JC, COMET D, MCCARTHY C: History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur. Urol. (2000) 37(2):183-190.
33. LUKACS B, GRANGE JC, MCCARTHY C, COMET D: Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice. Eur. Urol. (1998) 33(Suppl. 2):28-33.
34. SANCHEZ-CHAPADO M, GUIL M, BADIELLA LI, FERNANDEZ-HERNANDO N, ALFARO V: The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int. (2000) 86(4):432-438.
35. LUKACS B, GRANGE JC, COMET D, MCCARTHY C: Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice. Prostate Cancer Prostatic Dis. (1998) 1(5):276-283.
36. HOFNER K, JONAS U: Alfuzosin: a clinically uroselective alpha1-blocker. World J. Urol. (2002) 19(6):405-412.
37. MCKEAGE K, PLOSKER GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs (2002) 62(4):633-653.
38. VAN KERREBROECK P, JARDIN A, LAVAL KU, VAN CANGH P: Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur. Urol. (2000) 37(3):306-313.
39. MCKEAGE K, PLOSKER GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs (2002) 62(4):633-653.
40. SANOFI-SYNTHELABO CANADA INC: Xatral product monograph: alfuzosin hydrochloride prolonged-release tablets 10 mg. Revised December 2004.
41. HANSEN BJ, MORTENSEN S, MENSINK HJ et al.: Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group. Br. J. Urol. (1998) 81(1):36-41.
42. CORCOS J, BEAULIEU S, DONOVAN J et al.: Quality of life assessment in men and women with urinary incontinence. J. Urol. (2002) 168:896-905.
43. O'LEARY MP, FOWLER FJ, LENDERKING WR et al.: A brief male sexual function inventory for urology. Urology (1995) 46:697-706.
44. MARKS LS, ROEHRBORN CG, GITTELMAN M, KIM D, FORREST J, JACOBS S: First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. Urology (2003) 62(5):888-893.
45. ROEHRBORN CG: Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology (2001) 58(6):953-959.
46. VAN KERREBROEC P, JARDIN A, VAN CANGH P, LAVAL KU, THE ALFORTI STUDY GROUP: Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur. Urol. (2002) 41:54-61.
47. ROEHRBORN CG, VAN KERREBROECK P, NORDLING J: Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. (2003) 92(3):257-261.
48. LUKACS B, GRANGE JC, COMET D: One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. Urology (2000) 55(4):540-546.
49. LUKACS B, LEPLEGE A, THIBAULT P, JARDIN A: Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology (1996) 48(5):731-740.
50. EMBERTON M, ELHILALI M, MATZKIN H et al.: Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology (2005) 66(2):316-322.
51. VAN MOORSELAAR RJ, HARTUNG R, EMBERTON M et al.: Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int. (2005) 95(4):603-608.
52. ELHILALI M, EMBERTON M, MATZKIN H et al.: Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in real life practice. BJU Int. (In press).
53. JACOBSEN SJ, JACOBSON DJ, GIRMAN CJ et al.: Natural history of prostatism: risk factors for acute urinary retention. J. Urol. (1997) 158(2):481-487.
54. GIRMAN CJ, EPSTEIN RS, JACOBSEN SJ et al.: Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology (1994) 44:825-831.
55. SHAH T, PALIT V, BIYANI S, ELMASRY Y, PURI R, FLANNIGAN GM: Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur. Urol. (2002) 42(4):329-332.
56. PICKARD R, EMBERTON M, NEAL DE: The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br. J. Urol. (1998) 81(5):712-720.
57. ANNEMANS L, CLEEMPUT I, LAMOTTE M, MCNEILL A, HARGREAVE T: The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. BJU Int. (2005) 96(4):566-571.
58. MCNEILL SA: Does acute urinary retention respond to alpha-blockers alone? Eur. Urol. (2001) 39 (Suppl. 6):7-12.
59. SCHULMAN CC: Long-term aspects of medical treatment of BPH. Eur. Urol. (2001) 40(Suppl. 3):8-12.
60. MCNEILL SA, HARGREAVE TB, ROEHRBORN CG: Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology (2005) 65(1):83-89.
61. MCNEILL SA, DARUWALA PD, MITCHELL ID, SHEARER MG, HARGREAVE TB: Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. BJU Int. (1999) 84(6):622-627.
62. DJAVAN B, SHARIAT S, OMAR M: Does prolonged catheter drainage improve the chance of recovering voluntary voiding after acute urinary retention of urine (AUR)? Eur. Urol. (2003) 33(Suppl. 1):110.
63. BUZELIN JM, HEBERT M, BLONDIN P: Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. Br. J. Urol. (1993) 72(6):922-927.
64. BUZELIN JM, FONTEYNE E, KONTTURI M, WITJES WP, KHAN A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br. J. Urol. (1997) 80(4):597-605.
65. NORDLING J: Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. (2005) 95(7):1006-1012.
66. DEBRUYNE FM, JARDIN A, COLLOI D et al.: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur. Urol. (1998) 34(3):169-175.
67. WORLD HEALTH ORGANIZATION: The constitution of the World Health Organization. World Health Organ. Chron. (1947) 1:29.
68. BERZON R, HAYS RD, SHUMAKER SA: International use, application and performance of health-related quality of life instruments. Qual. Life Res. (1993) 2:367.
69. ROSEN R, ALTWEIN J, BOYLE P et al.: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. (2003) 44(6):637-649.
70. VALLANCIEN G, EMBERTON M, HARVING N, VAN MOORSELAAR RJ: Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J. Urol. (2003) 169(6):2257-2261.
71. NICKEL JC, ELHILALI M, VALLANCIEN G, FOR THE ALF-ONE STUDY GROUP: Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int. (2005) 95:571-574.
72. LARSON TR: Current treatment options for benign prostatic hyperplasia and their impact on sexual function. Urology (2003) 61(4):692-698.
73. NARAYAN P, LEPOR H: Long-term, open-label, Phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology (2001) 57:466-470.
74. NICKEL JC, FRADET Y, BOAKE RC et al.: Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). Can. Med. Assoc. J. (1996) 155:1251-1259.
75. KASSABIAN VS: Sexual function in patients treated for benign prostatic hyperplasia. Lancet (2003) 361:60-62.
76. VAN MOORSELAAR R, EMBERTON M, HARVING N et al.: Alfuzosin 10 mg once daily improves sexual function in men with LUTS and concomitant sexual dysfunction [Abstr.]. Eur. Urol. (2003) 1(Suppl. 2):74.
77. ANON: Alfuzosin (Uroxatral)-Another alpha-1 blocker for benign prostatic hyperplasia. The Medical Letter (2004) 46(1173):1-2.
78. Impact of BPH medical treatment on sexual function: Symposium; urogenital health: a new paradigm for male integrated core. XXth Congress of the European Association of Urology. Istanbul, Turkey (17 March 2005).
79. BUZELIN JM, DELAUCHE CAVALLIER MC, MARTIN D, ANGEL I: Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction. Br. J. Urol. (1998) 81(4):655-656.
80. WEINER DM, LOWE FC: Alfuzosin for the management of benign prostate hyperplasia. Expert Opin. Pharmacother. (2003) 4(11):2057-2063.
81. CHANG DF, CAMPBELL JR: Intraoperative floppy iris syndrome associated with tamsulosin. J. Cataract Refract. Surg. (2005) 31:664-673.
82. DESAGER JP, HARVENGT C, BIANCHETTI G, ROSENZWEIG P: The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. Int. J. Clin. Pharmacol. Ther. Toxicol. (1993) 31(11):568-571.
83. BIANCHETTI G, PADOVANI P, COUPEZ JM et al.: Pharmacokinetic interaction between hydrochlorothiazide, atenolol and alfuzosin: a new antihypertensive drug. Acta Pharmacol. Toxicol. (1986) 59(Suppl. 5):197-205.
84. WILDE MI, FITTON A, MCTAVISH D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs (1993) 45(3):410-429.
85. BRAUN MH, SOMMER F, HAUPT G, MATHERS MJ, REIFENRATH B, ENGELMANN UH: Lower urinary tract symptoms and erectile dysfunction: comorbidity or typical 'aging male' symptoms? Results of the 'Cologne Male Survey'. Eur. Urol. (2003) 44:588-594.
86. KLONER RA, JACKSON G, EMMICK JT et al.: Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J. Urol. (2004) 172(5 Pt 1):1935-1940.
87. YASSIN A, DIEDE H: Combination therapy: alpha1-adrenoceptor blockade and tadalafil in BPH population. European Society of Sexual Medicine (ESSM). Istanbul, Turkey (16 - 19 November 2003).
88. HARTUNG R, MATZKIN H, ALCARAZ A et al.: Age, comorbidity and anthypertensive comedication do not affect cardiovascular tolerability of alfuzosin 10 mg once daily. J. Urol. (2006) 175(2):624-628.